Crossmark

Hybrid mass spectrometry methods reveal lot-to-lot differences and delineate the effects of glycosylation on the tertiary structure of Herceptin®

Published Online: 2019

Authors

Upton, Rosie https://orcid.org/0000-0001-7204-2910
Migas, Lukasz G. https://orcid.org/0000-0002-1884-6405
Pacholarz, Kamila J. https://orcid.org/0000-0003-2712-7557
Beniston, Richard G.

Estdale, Sian https://orcid.org/0000-0003-4374-5320
Firth, David https://orcid.org/0000-0003-3558-2955
Barran, Perdita E. https://orcid.org/0000-0002-7720-586X
Funding

Funding for this research was provided by:

Biotechnology and Biological Sciences Research Council (BB/L015048/1, BB/K017802/1, BB/H013636/1, BB/M017702/1)
License Information

Version of Record valid from 2019-01-17
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

RELATED DATA

: Supplementary Information

IDENTIFIERS

: Rosie Upton (ORCID)

: Lukasz G. Migas (ORCID)

: Kamila J. Pacholarz (ORCID)

: Sian Estdale (ORCID)

: David Firth (ORCID)

: Perdita E. Barran (ORCID)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 12 November 2018; Accepted 12 January 2019; Accepted Manuscript published 17 January 2019; Advance Article published 23 January 2019; Version of Record published 27 February 2019

Document is current